FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
NEWARK, Calif., March 03, 2016 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9 and at the 28th Annual ROTH Conference on Wednesday, March 16.
| Cowen and Company 36th Annual Health Care Conference | |||||
| Date: | Wednesday, March 9 | ||||
| Time: | 9:20am – 9:50am Eastern Time | ||||
| Place: | Boston Marriott Copley Place, Boston, MA | ||||
| Webcast: | http://ir.cymabay.com/events | ||||
| 28th Annual ROTH Conference | |||||
| Date: | Wednesday, March 16 | ||||
| Time: | 10:00am – 10:30am Pacific Time | ||||
| Place: | The Ritz Carlton, Orange County, CA | ||||
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
